Sector focus: pharma

Bond issuance from the pharmaceutical sector has hit $70 billion so far this year, with investors clamouring for exposure to these highly rated non-cyclical names. 

Is it ironic, or simply logical, that an industry which aspires to cure all ills should thrive on what's bad for everyone else? Either way, in a beleaguered world, the pharmaceuticals sector has been a radiant light in M&A, in equities and, most of all, in the bond markets.

If anyone needed reminding, along came market leader Pfizer

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to View our subscription options

If you already have an account, please sign in here.

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here